Patents by Inventor Shigeru Akasofu

Shigeru Akasofu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240034777
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 1, 2024
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 11578120
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: February 14, 2023
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Publication number: 20210024622
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 28, 2021
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10829547
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 10, 2020
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Publication number: 20190112365
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Publication number: 20190112364
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Publication number: 20100099714
    Abstract: The invention provides methods for treating, preventing, and delaying the onset of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Pick's disease, and the like), dementia, mild cognitive impairments, glaucoma, ocular hypertension, and pain (e.g., neuropathic pain, headaches, and the like) by administering therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists to patents in need thereof. The invention also provides combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists. Exemplary AMPA receptor antagonists include 1,2-dihydropyridine compounds, such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. Exemplary NMDA receptor antagonists include adamantane compounds, such as memantine.
    Type: Application
    Filed: March 5, 2008
    Publication date: April 22, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Hiroshi Yoshino, Takahisa Hanada, Shigeru Akasofu
  • Publication number: 20070021397
    Abstract: A protective agent for neurons of the central nervous system and a prophylactic and/or therapeutic agent for disorders in neurons of the central nervous system is provided, each including a compound represented by donepezil hydrochloride.
    Type: Application
    Filed: June 14, 2004
    Publication date: January 25, 2007
    Applicant: EISAI CO., LTD.
    Inventors: Shigeru Akasofu, Manami Kimura
  • Patent number: 6583138
    Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: June 24, 2003
    Assignee: Eisai Co., Ltd.
    Inventors: Mitsuaki Miyamoto, Tatsuya Yoshiuchi, Keizo Sato, Motohiro Soejima, Takashi Sato, Koichi Kikuchi, Hiroyuki Yoshimura, Katsuhiro Moriya, Yoshinori Sakuma, Shigeru Akasofu, Koji Yamada